创美药业(02289.HK)上半年营收达17.1亿元归母净利润4230.5万元
格隆汇8月22日丨创美药业(02289.HK)发布中期业绩，截至2019年6月30日止6个月，公司营业收入达17.1亿元人民币(下同)，归属于母公司股东的净利润4230.5万元，基本及稀释每股收益0.3917元。
公司的主要业务是于中国分销药品，而绝大部分营业收入来自药品分销。公司亦透过向供应商提供有关营销策略的谘询服务及有关信息服务赚取服务收入。截至2019年6月30日，分销网络覆盖7100名客户，其中577名为分销商，4,761名为零售药店，1762名为医院、诊所、卫生站及其他。
公司将建设创美药业(广州)医药分拣配送中心，立足粤港澳大湾区核心地带广州南沙，辐射珠三角。物流系统集成建设引入AS/RS系统等先进物流解决方案，结合集团已有的SAP系统，可实现仓配可视化管理，建立物流一体化网络运作模式，实现集团所有物流中心仓库间的联动。
医药分拣配送中心项目位于广州市南沙区东涌镇沥裕街33号，南沙区是连接珠江口岸城市群的枢纽。基于集团成熟的非招标市场运营模式，项目落成后可迅速投入运营，将极大提高公司供应链运营效率，客户关系维系和业务拓展能力，可满足医药行业监管日益严格的要求，顺应行业整合、流通环节缩短的趋势，符合本集团“深耕广东，辐射周边”发展战略。
凭籍良好的信誉和优质服务，集团于2019年2月获广东信用协会颁发的“2018企业品牌信用金鼎奖”，于2019年5月，获中国(广州)国际物流装备与技术展览会组委会颁发的“中国物流行业金蚂蚁创新奖”，及获广东省企业联合会与广东省企业家协会共同颁发的“广东省诚信示范企业”(2011–2018连续八年)，于2019年6月获中华全国工商业联合会医药业商会颁发的“2018年度中国医药行业医药商业百强”。
在当前经济下行，医药流通行业格局重构的环境下，公司相信，随着人民健康意识的增强，医疗需求不断增加，分级诊疗及互联网医疗加快推进，医药流通行业会迎来新的变化。公司将牢牢把握粤港澳大湾区的历史性发展机遇，坚持实施“深耕广东，辐射周边”的市场战略，建设全面覆盖广东省及周边地区的医药零售终端网络，从而促进公司的长远发展及未来赢利水平的提高。持续把握医药非招标市场未来增长潜力，加快推进成熟的医药非招标市场运营模式，致力提高医药供应链运营效率，降低医药流通成本，成为中国医药健康产业最具市场竞争力服务商。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
